Ensysce Biosciences, Inc. (ENSC)
0.4705
-0.04
(-7.93%)
USD |
NASDAQ |
Oct 23, 16:00
0.465
-0.01
(-1.17%)
After-Hours: 20:00
Ensysce Biosciences Profit Margin (Quarterly) : -220.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -220.8% |
| March 31, 2026 | -370.1% |
| December 31, 2025 | -147.1% |
| September 30, 2025 | -756.3% |
| June 30, 2025 | -126.4% |
| March 31, 2025 | -147.4% |
| December 31, 2024 | -273.4% |
| September 30, 2024 | 19.36% |
| June 30, 2024 | -1.08K% |
| March 31, 2024 | -1.02K% |
| December 31, 2023 | -680.5% |
| September 30, 2023 | -618.0% |
| June 30, 2023 | -456.5% |
| Date | Value |
|---|---|
| March 31, 2023 | -277.6% |
| December 31, 2022 | -382.1% |
| September 30, 2022 | -3.53K% |
| June 30, 2022 | -3.82K% |
| March 31, 2022 | -157.7% |
| December 31, 2021 | -613.8% |
| September 30, 2021 | -1.43K% |
| June 30, 2021 | -215.4% |
| March 31, 2021 | -363.8% |
| December 31, 2020 | 4.39% |
| September 30, 2020 | |
| June 30, 2020 | -38.72% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.25K% |
| Return on Assets | -295.9% |
| Return on Invested Capital | -971.0% |
| Gross Profit Margin (Quarterly) | 99.44% |
| Operating Margin (Quarterly) | -221.3% |
| Return on Net Operating Assets | -755.6% |